DiaMedica: Funding, Investors & Team (Oct 2026)
DiaMedica is a biopharmaceutical company focused on developing innovative treatments for stroke and other vascular diseases where no current therapies are available. The only universally approved stroke treatment is tissue plasminogen activator (tPA) which can only be administered to patients within 4.5 hours of acute ischemic stroke. However, a urine-derived form of human tissue kallikrein-1 (uKLK1) has been approved in China for up to 48 hours post-stroke by promoting cerebral vascular circulation, angiogenesis and inhibiting apoptosis. Published clinical studies have found uKLK1 is also effective in combination with tPA in stroke patients. DiaMedica’s DM199 has been administered to close to 100 patients and demonstrated a safe and well tolerated profile. The Company is preparing to advance its proprietary recombinant form of the naturally occurring uKLK1 into clinical testing for the treatment of stroke. The Company is also studying the potential of DM199 for the treatment of acute kidney injury and other vascular diseases.
DiaMedica has raised $67.5M across 2 funding rounds on record, the most recent an undisclosed round of $37.5M announced in Jun 2023.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
DiaMedica Company Profile and Key Stats
Latest funding round on record: Jun 2023.
DiaMedica Funding Rounds
DiaMedica raised $30.0M in a Post-IPO Equity announced in Sep 2021.
1.8 years later, an undisclosed round of $37.5M was announced in Jun 2023.
DiaMedica Founders and Leadership Team
Contact details for the DiaMedica team: 1 of 2 have an email address on file.
Start 14-day free trial →DiaMedica Funding Compared to Other Biotechnology Startups
DiaMedica's latest round of $37.5M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like DiaMedica in Biotechnology and Minneapolis
Companies Similar to DiaMedica
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
DiaMedica Funding FAQs
What does DiaMedica do?
DiaMedica is a biopharmaceutical company focused on developing innovative treatments for stroke and other vascular diseases where no current therapies are available. The only universally approved stroke treatment is tissue plasminogen activator (tPA) which can only be administered to patients within 4.5 hours of acute ischemic stroke. However, a urine-derived form of human tissue kallikrein-1 (uKLK1) has been approved in China for up to 48 hours post-stroke by promoting cerebral vascular circulation, angiogenesis and inhibiting apoptosis. Published clinical studies have found uKLK1 is also effective in combination with tPA in stroke patients. DiaMedica’s DM199 has been administered to close to 100 patients and demonstrated a safe and well tolerated profile. The Company is preparing to advance its proprietary recombinant form of the naturally occurring uKLK1 into clinical testing for the treatment of stroke. The Company is also studying the potential of DM199 for the treatment of acute kidney injury and other vascular diseases.
How much funding has DiaMedica raised?
DiaMedica has raised $67.5M across 2 rounds on record. The most recent is an undisclosed round of $37.5M announced in Jun 2023.
When did DiaMedica last raise funding?
DiaMedica's most recent funding round on record is an undisclosed round of $37.5M, announced in Jun 2023.
Who founded DiaMedica?
FundedIQ lists Jaan Saluvere (Founder) at DiaMedica.
Who is the CEO of DiaMedica?
Rick Pauls is listed as CEO at DiaMedica.
Where is DiaMedica headquartered?
DiaMedica is based in Minneapolis, Minnesota, United States.
How many employees does DiaMedica have?
DiaMedica is in the 11-50 employee band.
How does DiaMedica's funding compare to other Biotechnology startups?
DiaMedica's latest round of $37.5M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's DiaMedica Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for DiaMedica is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.